EWY Performance — iShares MSCI South Korea ETF
Data updated: 2026-07-27
EWY returned +109.38% year to date and +246.23% over one year to May 2026. Annualised returns are +52.18% over 3 years and +20.06% over 5 years. The fund beat its South Korea Equity category average: $100 invested three years ago grew to $352, against $308 for the category, and to $346 over one year, against $306. Volatility over the past three years was 41.10% a year. In the 12 months to May 2026 the fund took in a net $5.9B, and assets reached $24.14B.
EWY Growth of $100
What $100 invested in iShares MSCI South Korea ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the South Korea Equity category average over the same months.
| Period | EWY | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $346 | $306 |
| 3 years (Jun 2023 – May 2026) | $352 | $308 |
| 5 years (Jun 2021 – May 2026) | $250 | $216 |
| Since data start (Sep 2019 – May 2026) | $441 | $389 |
EWY Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +109.38% |
| 1 year | +246.23% |
| 3 years (annualised) | +52.18% |
| 5 years (annualised) | +20.06% |
EWY Annual Returns
Calendar-year total returns of iShares MSCI South Korea ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +109.38% |
| 2025 | +97.59% |
| 2024 | −20.79% |
| 2023 | +19.05% |
| 2022 | −26.70% |
| 2021 | −7.55% |
| 2020 | +39.72% |
| 2019 (Sep–Dec) | +19.48% |
EWY Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +26.3% | +21.8% | −20.3% | +31.5% | +30.0% | — | — | — | — | — | — | — |
| 2025 | +6.9% | +0.8% | −1.1% | +4.0% | +7.8% | +17.9% | +2.5% | −1.4% | +10.3% | +21.3% | −6.9% | +11.3% |
| 2024 | −9.6% | +8.7% | +4.0% | −6.2% | −1.9% | +7.2% | +0.9% | −1.8% | −1.4% | −7.9% | −3.9% | −9.1% |
| 2023 | +11.9% | −7.6% | +4.9% | −1.0% | +3.1% | +0.9% | +6.9% | −7.4% | −5.5% | −7.0% | +15.4% | +6.1% |
| 2022 | −7.6% | −0.3% | −0.6% | −6.5% | +2.8% | −16.0% | +4.8% | −3.6% | −18.5% | +8.5% | +17.2% | −5.3% |
| 2021 | +1.8% | +0.2% | +0.8% | +3.2% | −0.1% | +2.4% | −5.7% | −1.7% | −7.4% | −0.5% | −6.1% | +6.2% |
| 2020 | −6.5% | −7.8% | −11.9% | +9.3% | +2.5% | +7.4% | +6.6% | +3.7% | +2.1% | +0.6% | +17.0% | +14.9% |
| 2019 | — | — | — | — | — | — | — | — | +6.3% | +4.5% | −1.6% | +9.3% |
EWY Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 41.10%
- 3-year Sharpe ratio: 1.16 (vs 4.5% risk-free rate)
- Best month: +31.49% (Apr 2026)
- Worst month: −20.35% (Mar 2026)
EWY Fund Flows
Monthly money in and out of iShares MSCI South Korea ETF, from SEC Form N-PORT.
- 12-month net flow: $5.9B
- 12-month gross sales (incl. reinvestments): $9.3B
- Sales ÷ redemptions: 2.79×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $0 | $2.8B | −$2.8B |
| Apr 2026 | $442.0M | $89.5M | $352.5M |
| Mar 2026 | $1.8B | $186.5M | $1.6B |
| Feb 2026 | $2.8B | $0 | $2.8B |
| Jan 2026 | $1.7B | $0 | $1.7B |
| Dec 2025 | $530.1M | $0 | $530.1M |
| Nov 2025 | $476.6M | $0 | $476.6M |
| Oct 2025 | $216.6M | $0 | $216.6M |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $87.5M | $200.4M | −$112.9M |
| Jul 2025 | $265.9M | $0 | $265.9M |
| Jun 2025 | $996.8M | $0 | $996.8M |
EWY Assets Under Management
Net assets of iShares MSCI South Korea ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $24.14B |
| 2026-02-28 | $17.95B |
| 2025-11-30 | $7.02B |
| 2025-08-31 | $5.09B |
| 2025-05-31 | $3.22B |
| 2025-02-28 | $3.20B |
| 2024-11-30 | $3.91B |
| 2024-08-31 | $5.07B |
| 2024-05-31 | $5.26B |
| 2024-02-29 | $4.67B |
| 2023-11-30 | $3.84B |
| 2023-08-31 | $3.65B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.